Objective-To perform a clinical and immunological study of patients with rheumatoid arthritis who develop subnormal serum immunoglobulins on gold treatment; to clarify the nature of the defect in antibody production and determine the natural history of this adverse reaction; to use this information to suggest guidelines for the detection, investigation, and management of this complication. patients who developed subnormal levels of one or more immunoglobulin isotypes while receiving gold treatment were recruited over a 10 year period from the practice of a single rheumatologist. Antibody production was assessed by measurement of total immunoglobulins and of specific antibody production against polysaccharide and protein antigens, with test immunisation if necessary. Results-Two broad patterns of antibody deficiency were identified: (1) (n = 11) mild, affecting only one immunoglobulin isotype and with normal specific antibody production. These patients were in general able to continue gold without further deterioration in antibody production.
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(Ann Rheum Dis 1996;55:616-621)
Moderate suppression of serum immunoglobulin levels occurs in approximately 50% ofpatients treated for rheumatoid arthritis with parenteral gold salts.' Development of significant immunoglobulin deficiency is also recognised as a complication of gold treatment, and both selective IgA deficiency and severe panhypogammaglobulinaemia have been described.2" Pathological immunoglobulin deficiency is generally considered to be a very rare consequence of gold therapy, although little systematic information is available on the incidence and natural history of this adverse reaction. In 1987, two patients with severe gold induced hypogammaglobulinaemia were reported from this unit.'Since that time, it has been our policy to measure serum immunoglobulins before starting gold treatment, after approximately six months of treatment, and annually thereafter (that is, after approximately every 1 g of gold given).
We report here a series of 22 patients who developed subnormal immunoglobulin levels on gold treatment, detected between 1985 and 1995. From our experience with these patients we suggest guidelines for the detection, investigation, and management of this complication and provide preliminary data on the prevalence and natural history.
Methods

STUDY POPULATION
Gold-induced immunoglobulin deficiency was defined as development of subnormal levels of one or more immunoglobulin isotypes in the course of gold treatment. Subnormal levels were defined as three standard deviations below the locally derived mean for a healthy adult population: IgG < 6.5 g litre-', IgA < 0.6 g litre-', and IgM < 0.4 g litre-'. All laboratory parameters of disease activity. Median duration of gold treatment before detection of decreased serum immunoglobulins was four years (range six months to 13 years) and the median total dose of gold given was 2.5 g (range 0.5 to 10 g).
Two broad patterns of immunoglobulin deficiency could be identified: (1) those with a decrease in serum immunoglobulins restricted to a single isotype and relatively mild immunodeficiency, and (2) those with a decrease in two or three isotypes and a high incidence of significant defects in specific antibody production. DECREASE '5 This reflects the perception that gold induced antibody defects are extremely rare. Our finding of 22 cases in a single unit over a 10 year period suggests that this adverse reaction may be more common than generally believed. We do not have a precise count of the number of patients treated with gold but the total is around 1000, suggesting that 2% or more of patients treated with gold develop antibody defects, a figure which we consider justifies a policy of screening immunoglobulin levels at least annually and in any patient presenting with recurrent or severe bacterial infection. Although some patients developed immunoglobulin deficiency in the early stages of gold treatment, the majority of the cases reported here had been on gold for two or more years, and two patients for more than 10 years, before the low immunoglobulins were detected. This suggests that monitoring of immunoglobulin levels is required throughout gold treatment.
The natural history of gold induced antibody deficiency has not previously been delineated. The cases reported here suggest that patients with mild defects and with normal specific antibody production can usually be maintained on gold treatment with no further decline in immunoglobulin production.
Patients who discontinue gold treatment because of a severe defect in total antibody production will usually recover normal immunoglobulin concentrations and specific antibody production, although a proportion show no evidence of recovery one year or more following discontinuation of gold, and in one patient (case 19), a persistent specific antibody defect was still apparent after three years . No clear relation was seen between duration and dose of gold treatment and time for recovery of immunoglobulin production; recovery time did, however, seem to be slower in those subjects with severe antibody defects. Recovery times varied between two months (case 20) and two years (case 13).
Gold is known to produce moderate decrements in immunoglobulin in the majority of patients treated,' suggesting that overt antibody deficiency may represent differential susceptibility to a pharmacological action of the drug rather than an idiosyncratic response to gold. One of the patients reported here (case 18) and previously8 had a partial deficiency of IgG3 predating treatment with gold, suggesting that minor defects in immunoglobulin synthesis might predispose to more severe defects while on gold treatment. No patient in our series had abnormal total immunoglobulins before treatment, but unfortunately no data are available on pretreatment IgG subclass or specific antibody activity for the remainder of the patients.
Defects in immunoglobulin production have been described with other second line drugs used in the treatment of rheumatoid arthritis.3 16 It is our impression that antibody deficiency is very much more common following gold treatment than with other drugs. Over the time period of this study we have only been aware of immunoglobulin deficiency developing in two patients on penicillamine, in one on methotrexate, and in no patients on sulphasalazine. However, this impression may be distorted by the frequency of use of these drugs in our unit and the relative infrequency of immunoglobulin measurement in patients on drugs other than gold.
Our policy for screening, investigation, and management of gold induced antibody deficiency has evolved with our clinical experience. In fig 3 we 
